跳转至内容
Merck
CN

PHR1624

Supelco

顺铂

Pharmaceutical Secondary Standard; Certified Reference Material

别名:

顺铂, 顺-二氯二氨基铂(II), 顺式-二胺二氯铂, 顺氯氨铂

登录查看公司和协议定价


About This Item

线性分子式:
Pt(NH3)2Cl2
CAS号:
分子量:
300.05
EC 号:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

certified reference material
pharmaceutical secondary standard

质量水平

Agency

traceable to Ph. Eur. C2210000
traceable to USP 1134357

API类

cisplatin

CofA

current certificate can be downloaded

包装

pkg of 200 mg

技术

HPLC: suitable
gas chromatography (GC): suitable

mp

270 °C (lit.)

应用

pharmaceutical (small molecule)

格式

neat

储存温度

2-30°C

SMILES字符串

N.N.Cl[Pt]Cl

InChI

1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2

InChI key

LXZZYRPGZAFOLE-UHFFFAOYSA-L

正在寻找类似产品? 访问 产品对比指南

一般描述

用于质量控制的制药二级标准品,为制药实验室和制造商制备内部工作标准品提供了一种方便、高性价比的替代方案。
顺铂是抗肿瘤药,用于治疗各种恶性肿瘤患者。

应用

这些二级标准品是经过检验的认证标准物质(CRM)。它们适用于多种分析应用,包括但不限于药物释放测试、药物的定性和定量分析方法开发、食品和饮料质量控制检测以及其他校准需求。
顺铂可用作分析参考标准品,通过高效液相色谱测定法测定血浆、癌细胞和肿瘤样品中的分析物。

生化/生理作用

强效的铂基抗肿瘤剂。与 DNA 二核苷酸 d(pGpG) 形成细胞毒性加合物,诱导链内交联。

分析说明

这些二级标准提供了有效的美国药典、欧洲药典和英国药典一级标准的多重可追溯性。

其他说明

该认证参考物质(CRM)根据ISO 17034ISO/IEC 17025进行生产和认证。有关此CRM使用的所有信息均可在分析证书上找到。

附注

要查看该材料的分析证书示例,请在下面的栏位中输入LRAB7778。这只是一个示例证书,可能不是您收到的批次。

象形图

Skull and crossbonesHealth hazard

警示用语:

Danger

危险分类

Acute Tox. 2 Oral - Carc. 1B - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

靶器官

Respiratory system

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

A high-performance liquid chromatographic assay for determination of cisplatin in plasma, cancer cell, and tumor samples.
Lopez-Flores A, et al.
Journal of Pharmacological and Toxicological Methods, 52(3), 366-372 (2005)
Sonja Ludwig et al.
Cancer immunology, immunotherapy : CII, 68(7), 1133-1141 (2019-05-30)
Advanced oral squamous cell carcinomas (OSCC) have limited therapeutic options. Although immune therapies are emerging as a potentially effective alternative or adjunct to chemotherapies, the therapeutic efficacy of combination immune chemotherapies has yet to be determined. Using a 4-nitroquinolone-N-oxide (4NQO)
Sample handling for determination of free platinum in blood after cisplatin exposure.
Johnsson A, et al.
Cancer Chemotherapy and Pharmacology, 41(3), 248-251 (1997)
Adrián E Granada et al.
Molecular biology of the cell, 31(8), 845-857 (2020-02-13)
DNA-damaging chemotherapeutics are widely used in cancer treatments, but for solid tumors they often leave a residual tumor-cell population. Here we investigated how cellular states might affect the response of individual cells in a clonal population to cisplatin, a DNA-damaging
Jessica M Rusert et al.
Cancer research, 80(23), 5393-5407 (2020-10-14)
Medulloblastoma is among the most common malignant brain tumors in children. Recent studies have identified at least four subgroups of the disease that differ in terms of molecular characteristics and patient outcomes. Despite this heterogeneity, most patients with medulloblastoma receive

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门